Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma

被引：17

作者：

Backe, J ^{[1
]}

Gassel, AM ^{[1
]}

Krebs, S ^{[1
]}

Muller, T ^{[1
]}

Caffier, H ^{[1
]}

机构：

[1] UNIV WURZBURG,INST PATHOL,D-8700 WURZBURG,GERMANY

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 1997年 / 259卷 / 04期

关键词：

immunohistochemistry; HER-2/neu; p53; Ki-S1; endometrial carcinoma;

D O I：

10.1007/BF02505331

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Expression of the HER-2/neu proto-oncogene product was looked for immunohistochemically in 222 endometrial carcinomas in a retrospective followup study. The intensity of protein expression was correlated with patient survival. Median follow-up time was 4.8 years. In 109 (49%) of 222 endometrial carcinomas there was aberrant expression of HER-2/neu. HER-2/neu-expression did not correlate with p53-expression and proliferation rate, as determined immunohistochemically by the monoclonal antibody Ki-S1. In univariate statistical analysis aberrant HER-2/neu expression was not predictive of adjusted survival (p=0.18) and of disease-free survival (p=0.42). In multivariate analysis HER-2/neu-expression was not found to be an independent prognosticator (p=0.099) as compared to FIGO-stage (p=0.0001), histologic grade (p=0.00099) and proliferation rate (p=0.0013). Therefore immunohistochemically detected expression of HER-2/neu seems not to be a clinical prognosticator in endometrial cancer.

引用

页码：189 / 195

页数：7

共 24 条

[1]

Announcements, 1989, Gynecologic Oncology, V35, P125, DOI [DOI 10.1016/0090-8258(89)90027-9, 10.1016/0090-8258(89)90027-9]

[2]

BACKE J, 1997, IN PRESS ZENTRALBL G

[3] OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].